Lowest Price Guaranteed From USD 4,899
Published
January 2020
Pages
274
View Count
8797
 |
 |
 |
 |
 |
 |
 |
 |
Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability (via the 505(b)(2) pathway), the demand for novel bioavailability enhancement methods has grown significantly.
To cater to this increasing demand, several contract manufacturers and technology providers have emerged in this domain. With more than 150 companies offering technologies / services for bioavailability enhancement, the market is highly fragmented; having said that, several mergers / acquisitions have also taken place as stakeholders strive to broaden their respective service portfolios. A number of players have developed novel, state-of-the art technologies to maintain a competitive edge in this rapidly emerging market. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace. In fact, since 2010, more than 4,000 articles, evaluating various bioavailability enhancement technologies have been published across several reputed journals. In addition, more than 6,000 patents have been filed post 2010, providing a significant scientific push to the development of novel approaches.
The ‘Bioavailability Enhancement Technologies and Services Market, 2020-2030’ report provides a comprehensive study on the current scenario of technologies and contract services related to bioavailability enhancement. The study features an elaborate discussion on the novel approaches adopted by different players offering solutions for altering the bioavailability of various drugs. Amongst other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as likely number of candidates in BCS II and IV, likely adoption rates of bioavailability enhancement approaches, expected trend in outsourcing and likely pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. To account for the uncertainties associated with the expected future demand and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the bioavailability enhancement technologies and services market in the short-mid and long term.
Chapter 3 is a general introduction to bioavailability. In this section, we have discussed, in detail, the concept of bioavailability and the current problems associated with bioavailability across various drug compounds. The chapter also features a detailed discussion on the current approaches being used for bioavailability enhancement.
Chapter 4 provides a comprehensive review of the global landscape of bioavailability enhancement technologies and service providers. It includes information related to over 150 companies that are currently operating in this domain. It features an in-depth market review, including a study of the regional distribution of players, analysis by company size and year of establishment, approach adopted for bioavailability enhancement, type of drug dosage form, route of administration, and the location of the company.
Chapter 5 features detailed profiles of some of the key players that are active in this domain and offer a wide range of services. Each profile presents an overview of the company, its financial information ( if available ), details related to its service(s) portfolio, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.
Chapter 6 presents a benchmark analysis of all the players engaged in this domain. It highlights the capabilities of these companies in terms of their expertise across bioavailability enhancement. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.
Chapter 7 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this domain. In addition, we have highlighted the key players, on the basis of the number of collaborations and also discussed the expansion of services (via acquisitions / mergers) by key players.
Chapter 8 provides a comprehensive publication analysis, highlighting the recent trends in published literature related to bioavailability enhancement technologies. It presents a relative comparison of key technologies, on the basis of the trend in number of publications (CAGR) and the impact factors of the journals wherein these articles were published.
Chapter 9 provides detailed analysis of the patents that have recently been filed related to bioavailability enhancement technologies. The study also highlights the upcoming trends in innovation in this domain. In addition, it presents a high-level view on the valuation of these patents
Chapter 10 features an overview of the various ongoing clinical studies that are evaluating the bioavailability of various drug candidates that are currently under development. The chapter features a comprehensive view on the focus areas of these clinical studies, highlighting the key players involved as well.
Chapter 11 presents a detailed estimation of the likely demand for bioavailability enhancement technologies / services. It provides a comprehensive view in terms of the annual number of projects that are likely to require bioavailability enhancement in the period 2020-2030.
Chapter 12 provides a comprehensive market forecast analysis, highlighting the future potential of contract services for bioavailability enhancement till the year 2030. It features the likely distribution of the market based on [A] approach used for bioavailability enhancement (solid dispersion, size reduction, lipid-based approaches, and other approaches), [B] region (North America, Europe, Asia-Pacific and rest of the world), and [C] opportunity from drugs across different BCS classifications (BCS II and BCS IV).
Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of this market in the foreseen future.
Chapter 14 is a collection of transcripts of the discussions by various stakeholders across the public domain.
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Drug Bioavailability
3.2. Need For Bioavailability Enhancement
3.3. Assessment of Drug Bioavailability
3.3.1. Key Considerations for Bioavailability Assessment Studies
3.3.1.1. Absolute Bioavailability
3.3.1.2. Relative Bioavailability
3.3.1.3. Single and Multiple Dose Studies
3.3.1.4. Studies in Healthy Subjects and Patients
3.3.2. Bioavailability Assessment Methods
3.4. Factors Affecting Bioavailability
3.4.1. Drug Related Factors
3.4.2. Patient Physiology Related Factors
3.5. Bioavailability Enhancement Technologies
3.5.1. Historical Overview
3.5.2. Physical Technologies for Bioavailability Enhancement
3.5.2.1. Solid Dispersion
3.5.2.1.1. Classification
3.5.2.1.2. Preparation Methodologies
3.5.2.1.2.1. Hot Melt Extrusion
3.5.2.1.2.2. Melting / Fusion Method
3.5.2.1.2.3. Solvent Evaporation
3.5.2.1.2.4. Spray-Dried Dispersion
3.5.2.1.2.5. Solid Dispersion: Other Techniques
3.5.2.2. Nanosuspension Technology
3.5.2.2.1. Top Down Approach
3.5.2.2.2. Bottom up Approach
3.5.3. Chemical Technologies for Bioavailability Enhancement
3.5.3.1. Lipid Based Formulations
3.5.3.2. Metal Based Drug Delivery Systems
3.5.3.3. Polymer Based Drug Delivery Systems
3.5.4. Biological Technologies
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Bioavailability Enhancement: List of Service Providers
4.2.1. Distribution by Company Portfolio
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Year of Establishment
4.2.5. Distribution by Bioavailability Enhancement Principle
4.2.6. Distribution by Bioavailability Enhancement Approach
4.2.6.1. Distribution by Lipid Based Approaches
4.2.6.2. Distribution by Size Reduction Approaches
4.2.6.3. Distribution by Solid Dispersion Approaches
4.2.6.4. Distribution by Other Approaches
4.2.7. Distribution by Dosage Form
4.2.8. Distribution by Route of Administration
4.2.9. Heat Map Analysis of Service Providers
4.2.10. Distribution by Leading Players
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Lonza
5.2.1. Company Overview
5.2.2. Financial Performance
5.2.3. Services Portfolio
5.2.4. Bioavailability Enhancement Services Portfolio
5.2.5. Recent Partnerships
5.2.6. Future Outlook
5.3. Catalent
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Services Portfolio
5.2.4. Bioavailability Enhancement Services Portfolio
5.2.5. Recent Partnerships
5.2.6. Future Outlook
5.4. Ascendia Pharmaceuticals
5.4.1. Company Overview
5.4.2. Services Portfolio
5.4.3. Bioavailability Enhancement Services Portfolio
5.4.4. Future Outlook
5.5. Particle Sciences (Acquired by Lubrizol)
5.4.1. Company Overview
5.4.2. Financial Performance
5.4.3. Services Portfolio
5.4.4. Bioavailability Enhancement Services Portfolio
5.4.5. Recent Partnerships
5.4.6. Future Outlook
5.6. Juniper Pharma Services
5.6.1. Company Overview
5.6.2. Financial Performance
5.6.3. Services Portfolio
5.6.4. Bioavailability Enhancement Services Portfolio
5.6.5. Recent Partnerships
5.6.6. Future Outlook
5.7. Phosphorex
5.7.1. Company Overview
5.7.2. Financial Performance
5.7.3. Services Portfolio
5.7.4. Bioavailability Enhancement Services Portfolio
5.7.5. Recent Partnerships
5.7.6. Future Outlook
5.8. Kuecept (Acquired by Aptuit / Evotec)
5.8.1. Company Overview
5.8.2. Financial Performance
5.8.3. Services Portfolio
5.8.4. Bioavailability Enhancement Services Portfolio
5.8.5. Recent Partnerships
5.8.6. Future Outlook
5.9. Creative Biolabs
5.9.1. Company Overview
5.9.2. Financial Performance
5.9.3. Services Portfolio
5.9.4. Bioavailability Enhancement Services Portfolio
5.9.5. Recent Partnerships
5.9.5. Future Outlook
5.10. WuXi AppTec
5.10.1. Company Overview
5.10.2. Financial Performance
5.10.3. Services Portfolio
5.10.4. Bioavailability Enhancement Services Portfolio
5.10.5. Recent Partnerships
5.10.6. Future Outlook
6. BENCHMARK ANALYSIS
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups
6.3.1. Benchmark Analysis: North and South America, Peer Group I
6.3.2. Benchmark Analysis: North and South America, Peer Group II
6.3.3. Benchmark Analysis: North and South America, Peer Group III
6.3.4. Benchmark Analysis: Europe, Peer Group IV
6.3.5. Benchmark Analysis: Europe, Peer Group V
6.3.6. Benchmark Analysis: Asia-Pacific, Peer Group VI
6.3.7. Benchmark Analysis: Asia-Pacific, Peer Group VII
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Types of Partnerships
7.3. Bioavailability Enhancement: Analysis of Partnerships
7.3.1. Distribution by Year of Partnerships
7.3.2. Distribution by Type of Partnerships
7.3.3. Distribution by Most Active Companies
7.3.4. Distribution by Leading Acquirers
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Bioavailability Enhancement: Analysis of Publications
8.2.1. Distribution by Year of Publications
8.2.2. Distribution by Key Journals
8.2.3. Emerging Areas: Word Clouds
8.2.4. Analysis be Key Approaches
8.2.4.1. Distribution by Number of Publications
8.2.4.2. Distribution by Year of Publications
8.2.4.3. Distribution by Growth Rate
8.2.4.4. Bubble Chart Analysis
8.2.5. Distribution by Leading Publications
9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Bioavailability Enhancement: Analysis of Patents
9.3.1. Distribution by Publication Year
9.3.2. Distribution by Geographical Location
9.3.3. Distribution by CPC Classification
9.3.4. Emerging Areas: Word Cloud
9.3.5. Patent Valuation
9.3.6 Leading Citations
10. CLINICAL TRIALS ANALYSIS
10.1. Chapter Overview
10.2. Guidelines to Conduct Bioavailability Studies
10.3. Clinical Trials Analysis
10.3.1. Research Methodology
10.3.2. Distribution by Study Start Date
10.3.3. Distribution by Study Design
10.3.4. Distribution by Phase
10.3.5. Distribution by Trial Status
10.3.6. Distributions of Types of Molecules by Phase of Development
10.3.7. Distribution by Leading Players
10.3.8. Study Focus: Word Cloud
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Bioavailability Enhancement Opportunities
11.3. Research Methodology
11.4. Demand Analysis: New Chemical Entities (NCEs)
11.5. Demand Analysis: Generics
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall Bioavailability Enhancement Market, 2020-2030
12.4. Bioavailability Enhancement Market: Distribution by BCS Classification
12.4.1. Bioavailability Enhancement Market by BCS II Drugs
12.4.2. Bioavailability Enhancement Market by BCS IV Drugs
12.5. Bioavailability Enhancement Market: Distribution by Type of Bioavailability Enhancement Approach
12.5.1. Bioavailability Enhancement Market by Lipid Based Approaches
12.5.2. Bioavailability Enhancement Market by Size Reduction Based Approaches
12.5.3. Bioavailability Enhancement Market by Solid Dispersion Based Approaches
12.5.4. Bioavailability Enhancement Market by Other Bioavailability Enhancement Approaches
12.6. Bioavailability Enhancement Market: Distribution by Geographical Location
12.6.1. Bioavailability Enhancement Market in the Americas (North America / South America)
12.6.2. Bioavailability Enhancement Market in Europe
12.6.3. Bioavailability Enhancement Market in Asia-Pacific
12.6.4. Bioavailability Enhancement Market in Rest of the World
13. CONCLUSION
13.1. Challenges Associated with Low Solubility and Permeability of Drugs Has Led to Increasing Demand for Bioavailability Enhancement
13.2. The Market is Characterized by The Presence of Several Established Players, As Well As Small and Mid-Sized Companies in Different Geographies
13.3. Size Reduction, Solid Dispersion and Lipid Based Methods are Offered by Several Technology / Service Providers; Players Offering Other Approaches are Also Emerging
13.4. The Field Has Witnessed Increasing Partnership Activity As Multiple Players are Collaborating for Expanding Capabilities
13.5. Ongoing Advances Have Led to Rapid Innovation and Increase in Patent Filling Activity
13.6. The Rising Number of BCS II and BCS IV Drugs and Increasing Adoption of Different Approaches for Enhancement of Drug Bioavailability is Likely to Foster the Long-Term Growth
14. TRANSCRIPTS OF PUBLIC DISCUSSIONS
14.1. Chapter Overview
14.2. David Vodak, Vice President of Chemistry, Bend Research
14.3. John K Tilloston, Pharmaceutical and Nutritional Technical Business Director, ABITEC
14.4. Kaspar van den Dries, Senior Director Formulation Sciences and Martin Piest, Senior Formulation Scientist, Patheon
14.5. Anonymous, MilliporeSigma Process Solutions
14.6. Brent Moody, Principal Scientist, Science and Technology, Catalent Pharma Solutions
14.7. Anonymous, Sancilio Pharmaceuticals
14.8. Frank Romanski, BASF Pharma Solutions
14.9. Karl Kolter, BASF Pharma Solutions
15. APPENDIX 1: TABULAR DATA
16. APPENDIX 2: LIST OF COMPANIES
Figure 3.1 Biopharmaceutical Classification System
Figure 3.2 Biopharmaceutical Classification System: Change in Trends
Figure 3.3 Bioavailability Enhancement Technologies: Evolutionary Timeline
Figure 3.4 Different Designs to Study Drug Bioavailability
Figure 3.5 Single Dose Study to Evaluate Bioavailability
Figure 3.6 Multiple Dose Study to Evaluate Bioavailability
Figure 3.7 Bioavailability Assessment: Methodologies
Figure 3.8 Bioavailability Assessment: Factors Affecting Bioavailability
Figure 3.9 Solid Dispersion: Classifications
Figure 3.10 Solid Dispersion: Preparation Methodologies
Figure 3.11 Solid Dispersion: List of Drugs Prepared by Hot Melt Extrusion
Figure 3.12 Solid Dispersion: List of Drugs Prepared by Melting / Fusion
Figure 3.13 Solid Dispersion: List of Drugs Prepared by Solvent Evaporation
Figure 3.14 Solid Dispersion: List of Drugs Prepared by Spray-Dried Dispersion
Figure 3.15 Solid Dispersion: Melt Agglomeration Technique
Figure 3.16 Nanosuspension: Preparation Methodologies
Figure 3.17 Lipid Based Formulations: Classification
Figure 3.18 Biological Formulation Technologies
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach and Geography
Figure 4.2 Bioavailability Enhancement Service Providers: Geographical Landscape
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.4 Bioavailability Enhancement Service Providers: Cumulative Distribution by Year of Establishment
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Lipid Based Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Formulation Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 4.13 Bioavailability Enhancement Service Providers: Heat Map Analysis by Dosage Form and Bioavailability Enhancement Approaches
Figure 4.14 Bioavailability Enhancement Service Providers: Leading Players
Figure 4.15 Bioavailability Enhancement Service Providers: Dosage Form Wise Global Distribution of Leading Players
Figure 5.1 Lonza: Annual Revenues, 2013-2017 (CHF Billion)
Figure 5.2 Lonza: Custom Contract Manufacturing Services
Figure 5.3 Lonza: Bioavailability Enhancement Services Portfolio
Figure 5.4 Catalent: Annual Revenues, 2013– 2017 (USD Billion)
Figure 5.5 Catalent: Revenues by Product Types, 2017 (USD Million)
Figure 5.6 Catalent: Services Portfolio
Figure 5.7 Catalent: Bioavailability Enhancement Services Portfolio
Figure 5.8 Ascendia Pharmaceuticals: Services Portfolio
Figure 5.9 Ascendia Pharmaceuticals: Bioavailability Enhancement Services Portfolio
Figure 5.10 Particle Sciences: Services Portfolio
Figure 5.11 Particle Sciences: Bioavailability Enhancement Services Portfolio
Figure 5.12 Juniper Pharmaceuticals: Annual Revenues, 2013–2017 (USD Million)
Figure 5.13 Juniper Pharma Services: Services Portfolio
Figure 5.14 Juniper Pharma Services: Bioavailability Enhancement Services Portfolio
Figure 5.15 Phosphorex: Polymeric Nanoparticles Applications
Figure 5.16 Phosphorex: Bioavailability Enhancement Services Portfolio
Figure 5.17 Kuecept: Services Portfolio
Figure 5.18 Kuecept: Bioavailability Enhancement Services Portfolio
Figure 5.19 Creative Biolabs: Services Portfolio
Figure 5.20 Creative Biolabs: Bioavailability Enhancement Services Portfolio
Figure 5.21 WuXi AppTec: Annual Revenues, 2010–Q3 2015 (USD Million)
Figure 5.22 WuXi AppTec: Services Portfolio
Figure 5.23 WuXi AppTec: Bioavailability Enhancement Services Portfolio
Figure 6.1 Benchmark Analysis: Distribution of Industry Players by Year of Establishment and Geographical Location
Figure 6.2 Benchmark Analysis: American Companies, Peer Group I
Figure 6.3 Benchmark Analysis: American Companies, Peer Group II
Figure 6.4 Benchmark Analysis: American Companies, Peer Group III
Figure 6.5 Benchmark Analysis: European Companies, Peer Group IV
Figure 6.6 Benchmark Analysis: European Companies, Peer Group V
Figure 6.7 Benchmark Analysis: European Companies, Peer Group VI
Figure 6.8 Benchmark Analysis: Asian Companies, Peer Group VII
Figure 6.9 Benchmark Analysis: Asian Companies, Peer Group VIII
Figure 7.1 Bioavailability Enhancement Partnerships: Cumulative Year-wise Trend
Figure 7.2 Bioavailability Enhancement Partnerships: Distribution by Type of Collaboration
Figure 7.3 Bioavailability Enhancement Partnerships: Yearly Distribution by Type of Collaboration
Figure 7.4 Bioavailability Enhancement Partnerships: Distribution by Most Active Players
Figure 7.5 Bioavailability Enhancement Partnerships: Distribution by Key Acquirers
Figure 7.6 Bioavailability Enhancement Partnerships: Distribution by Key Acquirers and Year of Acquisitions
Figure 8.1 Bioavailability Enhancement Publications: Cumulative Year-Wise Trend
Figure 8.2 Bioavailability Enhancement Publications: Top 15 Journals
Figure 8.3 Bioavailability Enhancement Publications: Emerging Areas
Figure 8.4 Bioavailability Enhancement Publications: Distribution of Approaches by Number of Publications
Figure 8.5 Bioavailability Enhancement Publications: Distribution of Approaches by Year of Publication
Figure 8.6 Bioavailability Enhancement Publications: Distribution of Approaches by CAGR (2008-2017)
Figure 8.7 Bioavailability Enhancement Publications: Technology Wise Bubble Chart Analysis
Figure 9.1 Bioavailability Enhancement Patents: Distribution by Type of Patent
Figure 9.2 Bioavailability Enhancement Patents: Distribution by Type of Technology
Figure 9.3 Bioavailability Enhancement Patents: Cumulative Distribution by Year and Bioavailability Enhancement Approach
Figure 9.4 Bioavailability Enhancement Patents: Distribution by Patent CAGR and Bioavailability Enhancement Approach
Figure 9.5 Bioavailability Enhancement Patents: Distribution by Publication Year
Figure 9.6 Bioavailability Enhancement Patents: Year-wise Regional Distribution
Figure 9.7 Bioavailability Enhancement Patents: Cumulative Distribution by CPC Classification Symbol
Figure 9.8 Bioavailability Enhancement Patents: Emerging Areas
Figure 9.10 Bioavailability Enhancement Patents: Age of Patent
Figure 9.11 Bioavailability Enhancement Patents: Patent Valuation
Figure 9.12 Bioavailability Enhancement Patents: Geographical Patent Valuation
Figure 9.13 Bioavailability Enhancement Patents: Leading Players
Figure 10.1 Bioavailability Studies: Cumulative Year Wise Trend
Figure 10.2 Bioavailability Studies: Study Design
Figure 10.3 Bioavailability Studies: Clinical Trial Distribution
Figure 10.4 Bioavailability Studies: Trial Status Wise Distribution
Figure 10.5 Bioavailability Studies: Distribution of Molecules by Phase of Development
Figure 10.6 Bioavailability Studies: Leading Players
Figure 10.7 Bioavailability Studies: Study Focus
Figure 11.1 Demand Analysis: Enhanced Formulation Drug Approvals (2010-2015)
Figure 11.2 Demand Analysis: Likelihood of Approval
Figure 11.3 Demand Analysis: Distribution by Dosage Forms
Figure 11.4 Demand Analysis: Distribution of Types of Molecule by Phase of Development
Figure 11.5 Demand Analysis: Expected Phase wise BCS Distribution of Drugs (2030)
Figure 11.6 Demand Analysis: Expected Demand (NCEs)
Figure 11.7 Demand Analysis: Expected Demand (NCEs), Opportunity Segmentation by Technology (2025-2030)
Figure 11.8 Demand Analysis: Expected Demand (Generics)
Figure 11.9 Demand Analysis: Expected Demand (Generics), Opportunity Segmentation by Technology (2025-2030)
Figure 12.1 Bioavailability Enhancement Market: Cost of Bioavailability Enhancement,
Figure 12.2 Bioavailability Enhancement Market: Trends in Out-Sourcing
Figure 12.3 Overall Bioavailability Enhancement Market, 2020-2030: Base Scenario (USD Billion)
Figure 12.4 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Base Scenario (USD Billion)
Figure 12.5 Bioavailability Enhancement Market: Market Shares of Formulation Approaches, (2020, 2025, 2030)
Figure 12.6 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Base Scenario (USD Billion)
Figure 12.7 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Base Scenario (USD Billion)
Table 3.1 Solid Dispersion Method: List of Drugs
Table 3.2 Nanoparticles: List of Drugs
Table 3.3 Nanosuspensions: List of Drugs
Table 3.4 Liposome Based Formulations: List of Drugs
Table 3.5 Micelles Based Formulations: List of Drugs
Table 3.6 Micro-Emulsion Based Parenteral Formulations: List of Drugs
Table 3.7 Micro-Emulsion Based Oral Formulations: List of Drugs
Table 3.8 Lipid Based Oral Formulations: List of Drugs
Table 3.9 Metal Based Drug Delivery Approaches: List of Drugs
Table 3.10 Polymer Based Drug Delivery Approaches: List of Drugs
Table 3.11 Biological Formulation Technologies: List of Drugs
Table 4.1 Bioavailability Enhancement Service Providers: Information on Company Portfolio
Table 4.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approaches
Table 4.3 Bioavailability Enhancement Service Providers: Information on Lipid Based Approaches
Table 4.4 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 4.5 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Based Approaches
Table 4.6 Bioavailability Enhancement Service Providers: Information on Other Approaches
Table 5.1 Lonza: Future Outlook
Table 5.2 Catalent: Future Outlook
Table 5.3 Catalent: List of Upcoming Conferences
Table 5.4 Ascendia Pharmaceuticals: Future Outlook
Table 5.5 Particle Sciences: Future Outlook
Table 5.6 Juniper Pharma Services: Future Outlook
Table 5.7 Phosphorex: Future Outlook
Table 5.8 Creative Biolabs: Future Outlook
Table 5.9 WuXi AppTec: Future Outlook
Table 6.1 Benchmark Analysis: Peer Groups
Table 7.1 Bioavailability Enhancement: Partnerships, 2013-2020
Table 8.1 Bioavailability Enhancement: Leading Publications
Table 9.1 Bioavailability Enhancement Patents: Most Popular CPC Symbols
Table 9.2 Bioavailability Enhancement Patents: List of Top CPC Classifications
Table 9.3 Bioavailability Enhancement Patents: List of Top Leading Patents
Table 10.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 14. 1 Technology Selection for Enhancing Bioavailability
Table 15.1 Bioavailability Enhancement Service Providers: Distribution by Type of Bioavailability Approach and Geography
Table 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 15.3 Bioavailability Enhancement Service Providers: Cumulative Distribution by Year of Establishment
Table 15.4 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 15.5 Bioavailability Enhancement Service Providers: Distribution by the Type of Approach
Table 15.6 Bioavailability Enhancement Service Providers: Distribution by Lipid Based Approaches
Table 15.7 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 15.8 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Based Approaches
Table 15.9 Bioavailability Enhancement Service Providers: Distribution by Other Formulation Approaches
Table 15.10 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 15.11 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 15.12 Bioavailability Enhancement Service Providers: Heat Map Analysis by Dosage Form and Bioavailability Enhancement Approaches
Table 15.13 Lonza: Annual Revenues, 2013-2017 (CHF Billion)
Table 15.14 Catalent: Annual Revenues, 2013– 2017 (USD Billion)
Table 15.15 Catalent: Revenues by Product Types, 2017 (USD Million)
Table 15.16 Juniper Pharmaceuticals: Annual Revenues, 2013–2017 (USD Million)
Table 15.17 WuXi AppTec: Annual Revenues, 2010–Q3 2015 (USD Million)
Table 15.18 Benchmark Analysis: Distribution of Industry Players by Year of Establishment and Geographical Location
Table 15.19 Benchmark Analysis, Peer Group I: Distribution by Bioavailability Enhancement Principle
Table 15.20 Benchmark Analysis, Peer Group I: Distribution by Type of Bioavailability Approach
Table 15.21 Benchmark Analysis, Peer Group I: Distribution by Dosage Form
Table 15.22 Benchmark Analysis, Peer Group I: Distribution by Route of Administration
Table 15.23 Benchmark Analysis, Peer Group II: Distribution by Bioavailability Enhancement Principle
Table 15.24 Benchmark Analysis, Peer Group II: Distribution by Bioavailability Enhancement Approach
Table 15.25 Benchmark Analysis, Peer Group II: Distribution by Dosage Form
Table 15.26 Benchmark Analysis, Peer Group II: Distribution by Route of Administration
Table 15.27 Benchmark Analysis, Peer Group III: Distribution by Bioavailability Enhancement Principle
Table 15.28 Benchmark Analysis, Peer Group III: Distribution by Bioavailability Enhancement Approach
Table 15.29 Benchmark Analysis, Peer Group III: Distribution by Dosage Form
Table 15.30 Benchmark Analysis, Peer Group III: Distribution by Route of Administration
Table 15.31 Benchmark Analysis, Peer Group IV: Distribution by Bioavailability Enhancement Principle
Table 15.32 Benchmark Analysis, Peer Group IV: Distribution by Bioavailability Enhancement Approach
Table 15.33 Benchmark Analysis, Peer Group IV: Distribution by Dosage Form
Table 15.34 Benchmark Analysis, Peer Group IV: Distribution by Route of Administration
Table 15.35 Benchmark Analysis, Peer Group V: Distribution by Bioavailability Enhancement Approach
Table 15.36 Benchmark Analysis, Peer Group V: Distribution by Approach Type
Table 15.37 Benchmark Analysis, Peer Group V: Distribution by Dosage Form
Table 15.38 Benchmark Analysis, Peer Group V: Distribution by Route of Administration
Table 15.39 Benchmark Analysis, Peer Group VI: Distribution by Bioavailability Enhancement Principle
Table 15.40 Benchmark Analysis, Peer Group VI: Distribution by Bioavailability Enhancement Approach
Table 15.41 Benchmark Analysis, Peer Group VI: Distribution by Dosage Form
Table 15.42 Benchmark Analysis, Peer Group VI: Distribution by Route of Administration
Table 15.43 Benchmark Analysis, Peer Group VII: Bioavailability Enhancement Principle
Table 15.44 Benchmark Analysis, Peer Group VII: Distribution by Bioavailability Enhancement Approach
Table 15.45 Benchmark Analysis, Peer Group VII: Distribution by Dosage Form
Table 15.46 Benchmark Analysis, Peer Group VII: Distribution by Route of Administration
Table 15.47 Benchmark Analysis, Peer Group VIII: Distribution by Bioavailability Enhancement Principle
Table 15.48 Benchmark Analysis, Peer Group VIII: Distribution by Bioavailability Enhancement Approach
Table 15.49 Benchmark Analysis, Peer Group VIII: Distribution by Dosage Form
Table 15.50 Benchmark Analysis, Peer Group VIII: Distribution by Route of Administration
Table 15.51 Bioavailability Enhancement Partnerships: Cumulative Year-wise Trend
Table 15.52 Bioavailability Enhancement Partnerships: Distribution by Type of Collaboration
Table 15.53 Bioavailability Enhancement Partnerships: Distribution by Most Active Players
Table 15.54 Bioavailability Enhancement Partnerships: Distribution by Leading Acquirers
Table 15.55 Bioavailability Enhancement Publications: Cumulative Year-Wise Trend
Table 15.56 Bioavailability Enhancement Publications: Top 15 Journals
Table 15.57 Bioavailability Enhancement Publications: Distribution of Approaches by Number of Publications
Table 15.58 Bioavailability Enhancement Publications: Year-Wise Technology Distribution
Table 15.59 Bioavailability Enhancement Publications: Distribution of Approaches by CAGR (2008-2017)
Table 15.60 Bioavailability Enhancement Publications: Bubble Analysis
Table 15.61 Bioavailability Enhancement Publications: Distributions of Top Publications by Technology
Table 15.62 Bioavailability Enhancement Patents: Distribution by Type of Patent
Table 15.63 Bioavailability Enhancement Patents: Distribution by Type of Approach
Table 15.64 Bioavailability Enhancement Patents: Cumulative Distribution by Publication Years for Bioavailability Enhancement Approaches
Table 15.65 Bioavailability Enhancement Patents: Distribution by Bioavailability Enhancement Approach and Patent CAGR
Table 15.66 Bioavailability Enhancement Patents: Distribution by Publication Year
Table 15.67 Bioavailability Enhancement Patents: Year-Wise Regional Distribution
Table 15.68 Bioavailability Enhancement Patents: Age of Patent
Table 15.69 Bioavailability Enhancement Patents: Patent Valuation
Table 15.70 Bioavailability Studies: Cumulative Year Wise Trend
Table 15.71 Bioavailability Studies: Intervention of Study
Table 15.72 Bioavailability Studies: Purpose of Study
Table 15.73 Bioavailability Studies: Allocation of Study
Table 15.74 Bioavailability Studies: Masking of Study
Table 15.75 Bioavailability Studies: Clinical Trials Distribution
Table 15.76 Bioavailability Studies: Trial Status Wise Distribution
Table 15.77 Bioavailability Studies: Distribution of Types of Molecule by Phase of Development
Table 15.78 Bioavailability Studies: Leading Players
Table 15.79 Demand Analysis: Enhanced Formulation Drug Approvals (2010-2015)
Table 15.80 Demand Analysis: Likelihood of Approval
Table 15.81 Demand Analysis: Distribution by Dosage Forms
Table 15.82 Demand Analysis: Phase wise BCS Distribution of Drugs (2020)
Table 15.83 Demand Analysis: Expected Phase wise BCS Distribution of Drugs (2030)
Table 15.84 Demand Analysis: Expected Demand (NCEs)
Table 15.85 Demand Analysis: Expected Demand (NCEs), Opportunity Segmentation by Technology (2025-2030)
Table 15.86 Demand Analysis: BCS for Generic Drugs, 2013 Scenario
Table 15.87 Demand Analysis: BCS for Generic Drugs, 2020 Scenario
Table 15.88 Demand Analysis: BCS for Generic Drugs, 2030 Scenario
Table 15.89 Demand Analysis: Expected Demand (Generic Drugs)
Table 15.90 Bioavailability Enhancement Market: Trends in Bioavailability Enhancement Cost, 2020-2030 (USD Million)
Table 15.91 Bioavailability Enhancement Market: Drugs Adopting Out-Licensing Approach for Bioavailability Enhancement
Table 15.92 Overall Bioavailability Enhancement Market, 2020-2030: Conservative Scenario (USD Billion)
Table 15.93 Overall Bioavailability Enhancement Market, 2020-2030: Base Scenario (USD Billion)
Table 15.94 Overall Bioavailability Enhancement Market, 2020-2030: Optimistic Scenario (USD Billion)
Table 15.95 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Conservative Scenario (USD Billion)
Table 15.96 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Base Scenario (USD Billion)
Table 15.97 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Optimistic Scenario (USD Billion)
Table 15.98 Bioavailability Enhancement Market: Market Shares of Formulation Approaches, (2020, 2025, 2030)
Table 15.99 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Conservative Scenario (USD Billion)
Table 15.100 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Base Scenario (USD Billion)
Table 15.101 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Optimistic Scenario (USD Billion)
Table 15.102 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Conservative Scenario (USD Billion)
Table 15.103 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Base Scenario (USD Billion)
Table 15.104 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Optimistic Scenario (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Discounts available for multiple report purchases
sales@rootsanalysis.com